We are happy to announce that the Business Call to Action (BCtA) has recently published a case study on Sproxil.Our company joined BCtA with a commitment to mobilize US$4 million to expand efforts to empower patients and consumers in the fight against counterfeit medication in India and Kenya.

To learn more about Sproxil’s efforts at combating counterfeit drugs and promoting improved health care outcomes in key markets, you can download the case study HERE.